On September 16th, 2015, Science magazine published a feature on Deputy Scientific Director Nir Barzilai and the momentum of on the AFAR-supported Taming Aging with Metformin (TAME) clinical trial. Also featuring AFAR Scientific Director Steven Austad, PhD; and Board Members James Kirkland, MD, PhD; and S. Jay Olshansky, as well as 1993 AFAR Research Grant recipient Felipe Sierra, PhD, the piece highlighted their involvement with designing the first-ever clinical trial focused on the co-mortalities of age related disease.
Framed by their recent meeting with the FDA to encourage making aging an indicator to move metformin and other promising drugs into clinical trials, the article focused on both the revolutionary trial design and the potential outcomes of success for the TAME trial. With Dr. Olshansky referring to the study as “a fundamental sea change in how we look at aging and disease.”
Read the complete article here and check out other articles on TAME here.
Steven Austad, PhD, is a Distinguished Professor and Department Chair at the University of Alabama, Birmingham.
Nir Barzilai, MD, is the Director of the Institute for Aging Research at Albert Einstein College of Medicine and a two-time AFAR grant recipient.
James Kirkland, MD, PhD, is the director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic and the 2012 recipient of a Glenn/AFAR Breakthroughs in Gerontology Award.
Felipe Sierra, PhD, is the Director of the Division of Aging Biology at the National Institute on Aging.
S. Jay Olshansky, PhD, is a Professor in the School of Public Health at the University of Illinois at Chicago and Research Associate at the Center on Aging at the University of Chicago and at the London School of Hygiene and Tropical Medicine.
